Genomics Reporting Implementation Guide
3.0.0 - STU3 International flag

This page is part of the Genetic Reporting Implementation Guide (v3.0.0: STU3) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version. For a full list of available versions, see the Directory of published versions

: ROS1-Fusion-therapuTrial - XML Representation

Raw xml | Download


<Observation xmlns="http://hl7.org/fhir">
  <id value="ROS1-Fusion-therapuTrial"/>
  <meta>
    <profile
             value="http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/therapeutic-implication"/>
  </meta>
  <text>
    <status value="extensions"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: Observation ROS1-Fusion-therapuTrial</b></p><a name="ROS1-Fusion-therapuTrial"> </a><a name="hcROS1-Fusion-therapuTrial"> </a><a name="ROS1-Fusion-therapuTrial-en-US"> </a><p><b>status</b>: Final</p><p><b>category</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/observation-category laboratory}">Laboratory</span>, <span title="Codes:{http://terminology.hl7.org/CodeSystem/v2-0074 GE}">Genetics</span></p><p><b>code</b>: <span title="Codes:{http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs therapeutic-implication}">Therapeutic Implication</span></p><p><b>subject</b>: <a href="Patient-somaticPatient.html">Substance Junior Hamsburg (official) Male, DoB: 1987-09-01 ( Medical record number: 1234567 (use: temp, period: 2021-01-01 --&gt; (ongoing)))</a></p><p><b>effective</b>: 2023-02-01</p><p><b>performer</b>: <a href="Practitioner-pathologistPractitioner.html">Practitioner Test Dolin </a></p><p><b>derivedFrom</b>: <a href="Observation-ROS1-Fusion-var.html">Observation Genetic variant assessment</a></p><blockquote><p><b>component</b></p><p><b>code</b>: <span title="Codes:{http://loinc.org 81259-4}">Associated phenotype</span></p><p><b>value</b>: <span title="Codes:{http://snomed.info/sct 254637007}">Non-small cell lung cancer</span></p></blockquote><blockquote><p><b>component</b></p><p><b>code</b>: <span title="Codes:{http://loinc.org 51963-7}">Medication assessed</span></p><p><b>value</b>: <span title="Codes:">Taletrectinib</span></p></blockquote><blockquote><p><b>component</b></p><p><b>code</b>: <span title="Codes:{http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs associated-therapy}">Associated Therapy</span></p><p><b>value</b>: <span title="Codes:{http://clinicaltrials.gov NCT04919811}">A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients With Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors</span></p></blockquote><blockquote><p><b>component</b></p><p><b>Related Artifact for Observation component</b>: No display for RelatedArtifact  (type: citation; url: https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/types-treatment)</p><p><b>code</b>: <span title="Codes:{http://loinc.org 93044-6}">Level of evidence</span></p><p><b>value</b>: <span title="Codes:">Tier I - Level A</span></p></blockquote></div>
  </text>
  <status value="final"/>
  <category>
    <coding>
      <system
              value="http://terminology.hl7.org/CodeSystem/observation-category"/>
      <code value="laboratory"/>
    </coding>
  </category>
  <category>
    <coding>
      <system value="http://terminology.hl7.org/CodeSystem/v2-0074"/>
      <code value="GE"/>
    </coding>
  </category>
  <code>
    <coding>
      <system
              value="http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs"/>
      <code value="therapeutic-implication"/>
    </coding>
  </code>
  <subject>🔗 
    <reference value="Patient/somaticPatient"/>
  </subject>
  <effectiveDateTime value="2023-02-01"/>
  <performer>🔗 
    <reference value="Practitioner/pathologistPractitioner"/>
  </performer>
  <derivedFrom>🔗 
    <reference value="Observation/ROS1-Fusion-var"/>
  </derivedFrom>
  <component>
    <code>
      <coding>
        <system value="http://loinc.org"/>
        <code value="81259-4"/>
      </coding>
    </code>
    <valueCodeableConcept>
      <coding>
        <system value="http://snomed.info/sct"/>
        <code value="254637007"/>
        <display value="Non-small cell lung cancer (disorder)"/>
      </coding>
      <text value="Non-small cell lung cancer"/>
    </valueCodeableConcept>
  </component>
  <component>
    <code>
      <coding>
        <system value="http://loinc.org"/>
        <code value="51963-7"/>
        <display value="Medication assessed"/>
      </coding>
    </code>
    <valueCodeableConcept>
      <text value="Taletrectinib"/>
    </valueCodeableConcept>
  </component>
  <component>
    <code>
      <coding>
        <system
                value="http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs"/>
        <code value="associated-therapy"/>
        <display value="Associated Therapy"/>
      </coding>
    </code>
    <valueCodeableConcept>
      <coding>
        <system value="http://clinicaltrials.gov"/>
        <code value="NCT04919811"/>
        <display value="NCT04919811"/>
      </coding>
      <text
            value="A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients With Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors"/>
    </valueCodeableConcept>
  </component>
  <component>
    <extension
               url="http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/workflow-relatedArtifactComponent">
      <valueRelatedArtifact>
        <type value="citation"/>
        <url
             value="https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/types-treatment"/>
      </valueRelatedArtifact>
    </extension>
    <code>
      <coding>
        <system value="http://loinc.org"/>
        <code value="93044-6"/>
        <display value="Level of evidence"/>
      </coding>
    </code>
    <valueCodeableConcept>
      <text value="Tier I - Level A"/>
    </valueCodeableConcept>
  </component>
</Observation>